Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for rare genetic diseases. Co.'s clinical programs consist of: EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. Co. has other AAV-based gene therapies in developmental stages designed to treat the CLN1 and CLN3 forms of Batten Disease, cystic fibrosis and retinal diseases. Co. is also developing AAV-based gene therapies through its AIM capsid platform and internal AAV vector research programs. The ABEO stock yearly return is shown above.
The yearly return on the ABEO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ABEO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|